United States · Biotechnology Research startup
United States · SELLAS Life Sciences Group, Inc.
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications.
Funding reportedLast round: Post ipo equity
About SELLAS Life Sciences Group, Inc.
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications.
SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
What company datasets say SELLAS Life Sciences Group, Inc. raised
Funding, as reported
Founders and team
From SELLAS Life Sciences Group, Inc.'s own website and the SEC filings it signed: 4 on the team.
- Andrew ElnatanSenior Vice President, Regulatory Affairs, CMC, and Quality
- Angelos M. StergiouExecutive Officer, Directori
- John T. BurnsExecutive Officeri
- Katherine Bach KalinBoard of Directors
On the board, as filediDavid A. ScheinbergJane Van WasmanJohn Van VarianRobert Van Nostrand
Biotechnology Research in United States
Startups like it
Is this your company?
Add your raise, your deck and your story, and put SELLAS Life Sciences Group, Inc. in front of investors. Or tell us what we have wrong.